Resistance to pharmacologic agents used in chemotherapy is common in most human carcinomas, including pancreatic ductal adenocarcinoma (PDA), which is resistant to almost all drugs, including gemcitabine, a nucleoside analog used as a first-line treatment. Poor survival rates of PDA patients have, therefore, not changed much over 4 decades. Recent data indicated that tumor-associated macrophages (TAMs), which are abundant in the microenvironment of several tumors, including PDA, secrete pro-tumorigenic factors that contribute to cancer progression and dissemination. In this study, we show for the first time that TAMs can also induce chemoresistance of PDA by reducing gemcitabine-induced apoptosis. Macrophages co-cultured with cancer cells or TAM-conditioned medium significantly reduced apoptosis and activation of the caspase-3 pathway during gemcitabine treatment.
INTRODUCTION
An unresolved problem in oncology is resistance of tumors to chemotherapeutic agents. Many human carcinomas are resistant to chemotherapy, with pancreatic ductal adenocarcinoma (PDA) being one of the most resistant among them.
1,2 Decades of effort have witnessed the failure of many chemotherapeutic regimens, and the current standard-of-care therapy, gemcitabine, extends PDA patient survival by only a few weeks. 3, 4 Acquired resistance to chemotherapy has been attributed to various mechanisms, including the high frequency of genetic mutations 5 and excessive activation of downstream signaling pathways. 6, 7 In the last decade, there has been growing understanding of the role of the tumor microenvironment in the progression of cancer in general, and in the stroma-rich PDA in particular. 8, 9 Tumorassociated macrophages (TAMs), which are abundant in PDAs, are derived from monocytes recruited to the tumor site and stimulated by specific chemokines secreted by tumor cells. 10 These TAMs have been postulated as being involved in the progression of cancer. [11] [12] [13] TAMs produce a number of potent angiogenic and lymphangiogenic growth factors, cytokines and proteases, all of which are mediators that potentiate neoplastic progression. [14] [15] [16] Studies of hematogenic malignancies also suggested that macrophages can mediate chemoresistance by direct interaction with myeloma cells in the tumor niche. 17, 18 TAMs can potentially influence the response to chemotherapy in a process known as environment-mediated drug resistance. [19] [20] [21] [22] [23] Gemcitabine (dFdC), the first-line drug for PDA, 24 is metabolized intracellularly by deoxycytidine kinase (dCK) to its active metabolites dFdCDP and dFdCTP. 5 Several mechanisms may be responsible for gemcitabine resistance: (1) loss of membranal transport by nucleoside transporters, (2) downregulation of dCK, the rate-limiting enzyme in the biotransformation to its active metabolites, (3) upregulation of cytidine deaminase (CDA), the enzyme that metabolizes dFdC to its inactive forms (dFdU), (4) upregulation of ribonucleotide reductase, which is used in the synthesis of DNA and (5) downstream inhibition of caspase executioners that control apoptosis signaling. response in PDA. Based on this observation and on previous studies indicating that macrophages may induce pro-tumoral signals, we investigated whether macrophages also have a role in triggering chemoresistance.
Macrophage-mediated drug resistance Human Panc1 cells were incubated in the following conditions: normal medium, naïve macrophage-conditioned medium (nMø-CM) or tumor-activated macrophage-CM (TAM-CM). Cells were exposed to increasing doses of gemcitabine to determine the dose-response curves in each condition. Figure 1 shows that nMø-CM and TAM-CM significantly reduced the sensitivity of Panc1 cells to gemcitabine by threefold (P ¼ 0.04). The median effective dose (ED 50 ) of gemcitabine was 5.36 mM when Panc1 cells were incubated in normal medium, 8 mM in nMø-CM and 18.24 mM in TAM-CM. These data suggested that soluble factor(s) secreted by TAMs induce gemcitabine resistance in PDA.
Next, we investigated whether drug resistance is mediated by reducing gemcitabine-induced apoptosis. Apoptosis was studied by FACS using annexin V-FITC and propidium iodide. Figure 2a shows a representative FACS analysis study in which nMø-CM and TAM-CM markedly reduced the percent of annexin V-positive PDA cells treated by 5 mM gemcitabine relative to normal medium. Figure 2b shows the summary of these experiments (n ¼ 4). These results were confirmed by studying the activation of the apoptosis-executioner protein caspase-3 in normal medium, nMø-CM and TAM-CM using an ELISA colorimetric assay. PDA cells treated with gemcitabine showed a twofold increase in caspase-3 activity in normal conditions (Figure 2c ). However, there was a statistically significant reduction in caspase-3 activity after exposure to gemcitabine with TAM-CM (Po0.001). Similar findings were found for other cell lines including AsPc and Hs766T human PDA cells. In the other hand, the capan-2 line was resistant to gemcitabine and hence was not affected by the CM (Supplementary Figure 1) . In agreement with the ELISA experiment, western blotting analysis of cleaved caspase-3 showed that TAM-CM inhibited activation of the caspase pathway ( Figure 2d ).
As MMDR may also be induced by cell-adhesion molecules, we further investigated the mechanism of gemcitabine resistance in co-cultures of PDA and macrophages. TAMs were distinguished from cancer cells by anti-CD11b antibodies and FACS sorting. The apoptosis rate of PDA cells grown in direct contact with macrophages was similar to the effect of TAM-CM and significantly lower than in control medium (data not shown). Since incubation in direct contact or with CM had a similar effect on apoptosis, the results of this experiment suggested that a soluble factor(s) is likely involved in MMDR.
Reduced effect of gemcitabine in macrophage-deficient mice Our in vitro experiments suggested that MMDR is mediated by the protective effect of TAMs against gemcitabine in PDA cells. We analyzed these results in vivo by evaluating tumor response to gemcitabine in wild-type (WT) and in CCR2
À / À mice. The chemokine (C-C motif) ligand-2 (CCL2) and its receptor CCR2 are widely expressed in a variety of cell types, including monocytes and macrophages. 28 We also bore in mind that CCR2 activity mediates the recruitment of macrophages to the tumor microenvironment, and that CCR2-deficient mice have reduced infiltration and activation of TAMs. 29 Immunofluorescence staining with anti-F4/80 antibodies, a macrophage marker, revealed a high rate of macrophage infiltration in the tumor microenvironment of the WT mice but not of the CCR2 À / À mice. We used an established orthotopic murine model of PDA 30 and employed the Panc2 cell line. WT and CCR2
À / À mice were randomly assigned to a gemcitabine or a vehicle treatment using an established protocol (gemcitabine 80 mg/kg or saline injected intraperitoneally (i.p.) bi-weekly for 2 weeks). 31 All mice were euthanized after 24 days, and their pancreases were excised for histopathologic analysis. Figure 3a shows the tumor volume for each mouse in the four study groups. The tumor response to gemcitabine in the WT animals was similar in the control and gemcitabine treatment groups. In contrast, the effect of gemcitabine was significantly more prominent in the CCR2 À / À animals compared with controls (P ¼ 0.001). Supplementary Figure 2 shows the ultrasound scans and tumor images.
To further evaluate the effect of TAM on gemcitabine resistance in vivo, primary PDA tumors were induced in C57/BL/6J mice by orthotopic inoculation of KPC4139 cells. Macrophage depletion was achieved as described earlier 32 using clodronate liposome, 48 h before first gemcitabine treatment (see Materials and methods). All the mice were treated for 5 weeks. Figure 3b shows that WT mice with depleted macrophages had smaller tumors after gemcitabine treatment compared with controls. Nonparametric Spearman Correlation Coefficient test was used to test the strength of the relationship between the number of TAMs per high power field (TAMs density) and tumor volume. We found a CSF1-receptor antagonist augmented the effect of gemcitabine Previous reports have indicated that PDA secretion of CSF1 participates in the recruitment of TAMs. 33, 34 We and others previously showed that inhibition of the CSF1-receptor (CSF1-R) significantly reduced the number of TAMs in PDA tumors. Based on these findings, we investigated whether GW2580, a selective small molecule kinase inhibitor of CSF1-R, 32 can augment the effect of gemcitabine by preventing MMDR. For this purpose, we utilized a transgenic animal model, which is based on mutations in the Kras and Trp53 genes and in the pancreas-specific promoter (Pdx-1) used to drive expression of Cre recombinase, which excises a Lox-STOP-Lox (LSL) upstream of the mutant alleles. We chose these LSL-Kras G12D/ þ ; LSL-p53 R172H/ þ ;Pdx-1-Cre mice (that is, KPC) because they develop preinvasive pancreatic lesions that progress into invasive PDA within 10 weeks of age at the earliest. 35 Animals with a tumor diameter of 5-10 mm were selected and matched for each arm by small animals' ultrasound. 31 Treatment groups included gemcitabine (80 mg/kg q3 days) þ vehicle (DMSO 0.1%) or gemcitabine þ GW2580 (80 mg/kg, b.i.d.). Mice were treated for 3 weeks and the tumor growth inhibition rate was calculated by ultrasound q3 days. Tumor measurement was performed in a blind manner by an independent person. Figure 3c shows the effect of gemcitabine with or without GW2580 on tumor volume of KPC mice. The tumor response was significantly larger in the combined gemcitabine and GW2580 arm compared with gemcitabine alone (Supplementary Table 1 ).
TAMs induced gemcitabine resistance by upregulation of CDA Next, we systematically investigated the impact of TAMs on proteins, which are known to be involved in gemcitabine resistance. 36 PDAs were incubated for 48 h with or without gemcitabine in the following conditioned: (1) normal media, (2) nMø-CM and (3) TAM-CM. Real-time PCR and western blotting analyses were used to evaluate the regulation of key proteins involved in gemcitabine transport and metabolism in each condition. The expression of the following genes was investigated: (1) Gemcitabine transporters, including CNT1 and ENT1; (2) dCK, which catalyzes the biotransformation of gemcitabine to its active metabolites; (3) ribonucleotide reductases, including RRM1 and RRM2, which catalyze the formation of deoxyribonucleotides; 37 and (4) CDA, which catalyzes the active metabolites of gemcitabine to its inactive metabolites. Figure 4a -e shows the minimal effect of TAM-CM on the expression of the following genes: CNT1b, ENT1, dCK, RRM1 and RRM2.
We then evaluated the effect of TAM-CM on the expression of CDA, the enzyme responsible for inactivation of gemcitabine. Panc1 cells were incubated with or without gemcitabine in normal media or in TAM-CM. Quantitative PCR analysis indicated that TAM-CM induced a 75-fold increase in CDA expression in the presence of gemcitabine ( Figure 5a ). Gemcitabine alone also induced a significant increase in CDA expression; however, CDA expression in cells incubated with gemcitabine and TAM-CM was significantly higher than the effect of gemcitabine and TAM-CM separately. To confirm the effect of TAMs on CDA expression in vivo, we implanted murine Panc2 cells in the pancreases of WT and CCR2
À / À C57BL-6 mice. The mice were treated with gemcitabine or vehicle for 10 days and their tumors were harvested and analyzed by immunocytochemistry staining with anti-CDA Ab. Figure 5b shows that there was a significant increase in CDA expression after gemcitabine treatment in WT animals compared with controls. But most importantly, there was minimal change in CDA expression in the CCR2 À / À mice. Next, we analyzed the effect of TAMs on proliferation, apoptosis and CDA expression using normal and macrophage-depleted mice. Immunostaining staining was performed using the following antibodies: anti-Ki67, a marker of cell proliferation; anti-activated caspase-3, a marker of apoptosis; and anti-CDA (for expression of CDA). The results are shown in Figure 5c .
Depletion of macrophages with liposome-encapsulated clodronate induced increased caspase-3 expression and decreased Ki67 and CDA expression compared with phosphate-buffered saline (PBS)-containing liposome, supporting our finding that TAMs induce gemcitabine resistance by induction of CDA.
Finally, to evaluate whether CDA is indeed involved in MMDR, we treated Panc1 cells with siRNA directed against CDA (siCDA) or control transcripts (siControl). siCDA inhibited the expression of CDA in cells treated with gemcitabine ( Figure 6a ). We used caspase-3 activity ELISA to estimate activation of apoptosis cascade in the siControl and siCDA-treated cells. Figure 6b shows that gemcitabine increased caspase-3 activity in siControl and siCDA-treated cells. However, TAM-CM inhibited caspase-3 activity in cells expressing siControl, the high level of caspase-3 activity persisted in the siCDA-treated cells. The results of this experiment indicate that MMDR was induced by soluble factors secreted by TAMs through upregulation of CDA expression, which increased degradation of gemcitabine.
DISCUSSION
PDA is a leading cause of cancer-related deaths and one of the few cancers for which survival has not improved over nearly 40 years. Despite improvement in our understanding of pathophysiological mechanisms leading to PDA development and dissemination, little progress has been made in improving survival of patients mainly due to its broad resistance to chemotherapy and late diagnosis. The primary treatment for patients with PDA is based on the nucleoside analog gemcitabine, which replaces the nucleoside molecule cytidine during DNA replication, resulting in apoptosis. Gemcitabine also irreversibly inactivates ribonucleotide reductase, thereby preventing the production of deoxyribonucleotides. Unfortunately, gemcitabine offered only a modest advantage over earlier treatments, and drug resistance remained a serious clinical problem among patients for whom surgery is not a valid option for cure. 38 In this study, we tested the hypothesis that the stroma in general and macrophages in particular have a role in the chemoresistance of PDA. The results of our in vitro and in vivo models show that TAMs can trigger upregulation of CDA in cancer cells, a gene responsible for the resistance to gemcitabine and cisplatin. This finding suggests that paracrine signals in the tumor microenvironment may be exploited by cancer cells to maintain malignant growth despite cytotoxic insults.
Promotion and maintenance of tumor growth and invasion depend on the tumor microenvironment, which provides a network of interactions between the cancer cells and various supporting cells (also known as the tumor's stroma). 39 The tumor stroma includes fibroblasts and inflammatory cells, which can support proliferation and dissemination of cancer. If the stroma is capable of nurturing tumor cells, then it is also possible that the same cells are also responsible for the resistance of cancer to chemotherapy. Indeed, recent data have indicated that fibroblasts may induce drug resistance of cancer cells by reducing blood supply to the tumor. 31 One recent study of the interactions between cancer cells and stromal cells revealed that the efficacy of anticancer drugs is markedly reduced when cancer cells are cocultured with stromal cells. 40 Macrophages, which are part of the tumor stroma, are recruited and activated by signals mediated by the cancer cells. 15 Despite increasing recognition of the involvement of macrophages in cancer invasion and progression, its role in chemotherapy resistance has received relatively little attention among researchers until recent years. Earlier studies on non-solid tumors had indicated that the sensitivity of myelomas to melphalan and mitoxantrone may be influenced by macrophages via soluble factors as well as direct cell contact. 17, 18 The first observation that macrophages can induce drug resistance to 6-thioguanine was observed in breast cancer cells in vitro. 41 It was recently shown that response of mammary tumor-bearing mice to chemotherapy can also be regulated by macrophages in CD8 þ T cell-dependent mechanisms. 42 Cathepsin-expressing macrophages in mammary tumors can also blunt the chemotherapeutic response against Taxol induced both in co-culture and in vivo. 43 A similar effect of CD11b þ cells against radiotherapy suggests that peritumoral recruitment of myeloid cells has an important role in environment-mediated resistance to treatment. 44, 45 Whereas the above-cited studies suggested that the mechanisms by which macrophages blunt the effects of chemotherapy are modulation of cellular immunity or activation of intracellular signaling pathways, we suggest a different mechanism, the modulation of the expression of drug-resistant genes by TAMs. In agreement with previous studies of breast cancer models, we also showed that inhibition of monocytes/macrophages recruitment by CSF1-R blocker significantly enhances the therapeutic 
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There are several potential factors in macrophage-conditioned medium, which can be involved in gemcitabine resistance. Data from phosphorylation array of 71 tyrosine kinase receptors (Raybio, Norcross, GA, USA, #AAH-PRTK-G1) performed on Panc1 cells incubated with macrophage-CM revealed a significant increase in the phosphorylation level of JAK3 and JAK1, a tyrosine kinase that belongs to the Janus family of kinases (Gil et al., unpublished data). Both JAK1 and JAK3 are activated by several cytokines including IL-4, which is secreted by M2 macrophages. 46, 47 Further evaluation of the effect of IL-4 on PDAC, and downstream JAK signaling is needed to investigate potential pathways mediating drug resistance.
In summary, our study provides the first line of evidence that TAMs have a central role in the chemoresistance to gemcitabine. Macrophages induce cancer chemoresistance through upregulation of CDA, an intracellular enzyme that metabolizes the active formation of gemcitabine. Chemokine and growth factor that are secreted by TAMs can potentially induce drug resistance through autocrine or paracrine mechanisms. 48, 49 Additional research is necessary to elucidate the nature of these interactions and the intracellular pathways that are involved. The clinical significance of such studies is substantial, as treatment directed against MMDR can be expected to improve the efficacy of chemotherapy, thereby prolonging patient survival and reducing disease morbidity.
MATERIALS AND METHODS

Cell cultures
The human pancreatic carcinoma cell lines were obtained from American Type Culture Collection (Rockville, MD, USA). The cell lines were maintained in continuous exponential growth by twice weekly passage in Dulbecco modified Eagle's medium (DMEM, Life Technologies, Inc., Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 10 mg/ml streptomycin in a humidified incubator containing 5% CO 2 in air at 37 1C. Each cell line was split regularly before attaining 70-80% confluence.
Generation of macrophage-CM
Macrophages were produced as previously described. 16 Briefly, mononuclear cells from the blood of healthy donors were incubated in 6-well plates for 2 h in PBS (60% confluence), at 37 1C to remove nonadherent cells. The adherent monocytes were incubated for 7 days in RPMI medium supplemented with 50 ng/ml M-CSF (Peprotech Inc., Rocky Hill, NJ, USA) to become nMøs. The nMøs were cultured for an additional 72 h with tumor culture conditioning medium of Panc1 cells to generate TAMs. Tumor culture conditioning medium was generated by incubating Panc1 cell (50% confluence) in serum-free RPMI medium for 48 h. To study soluble factor-induced MMDR, CM was produced by incubation of nMøs or TAMs in serum-free RPMI medium for 48 h. To study soluble factor-induced gemcitabine resistance, we incubated pancreas cancer cells in 48-well plates (40% confluence), with CM of nMøs or TAMs for 48 h.
Cell proliferation and apoptosis assays
Cells were seeded at a density of 15 000 cells/well in 48-well culture plates. After overnight incubation, the medium was removed and replaced with normal medium, nMø-CM or TAM-CM in the presence or absence of gemcitabine (Sigma, St Louis, MO, USA). After 72 h of incubation, the relative cell count was determined by XTT (Biological Industries, Beit Haemek, Israel). All samples were analyzed in triplicate.
For apoptosis assay, cells were incubated in normal medium, nMø-CM, TAM-CM or in co-cultures with nMøs in the presence or absence of 5 mM gemcitabine. After 72 h, the cells were harvested and washed twice with PBS, stained with annexin V-FITC and propidium iodide (MBL, Nagoya, Japan), and analyzed using a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The FITC( þ )PE( À ) cells were regarded as being early apoptotic, and the FITC( þ )PE( þ ) cells as late apoptotic/necrotic. The total apoptotic rate was calculated as the sum of the early and late apoptosis rates. For analyzing apoptosis of the co-cultured cells, the macrophages were tagged with an APC-labeled anti-human CD11b antibody (BioLegend, San Diego, CA, USA), which is a myeloid cell marker, and the Panc1 cells were selected for analysis by gating for the APC( À ) cell population (negative selection). 18 Caspase-3 detection was performed by an ELISA calorimetric assay (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol. Cells were seeded in 10-cm tissue culture plates at a density of 10 6 cells/plate. After overnight incubation, the medium was removed and cells were incubated in normal medium, nMø-CM or TAM-CM, with or without 5 mM gemcitabine. After another 72 h, the cells were harvested, lysed and treated according to the manufacturer's protocol. Caspase-3 activity was measured using the Spectra MR spectrophotometer (Dynex Technologies, Chantilly, VA, USA).
Animals
Four-to six-week-old female C57BL/CJ (Harlan, Jerusalem, Israel) and CCR2 À / À mice (The Jackson Laboratory, Bar Harbor, ME, USA) were used in all experiments according to the Association for Assessment and Accreditation of Laboratory Animal Care specifications. All experimental procedures were done in accordance with Institutional Animal Care and Use Committee and the Department of Agriculture regulations. Water and food were supplied ad libitum. The genotyping of all animals was confirmed by RT-PCR using standard protocols. The primers used for genotyping of the CCR2 À / À mice were CTACGATGATGGTGAGCCTTGTC (WT), AATGTGAGCAGGAAGAGCAGGTC (WT), ACCGCTTCCTCGTGCTTTAC (mutant) (Sigma).
Mice endogenously expressing a single mutant of KrasG12D and p53R172H alleles in progenitor cells of the pancreas were obtained from the NCI (National Cancer Institute) mouse repository (Frederick National Laboratory for Cancer Research, MD, USA). Briefly, LSL-KrasG12D p53R172H (KP) mice were bred with Pdx-1-Cre mice that express Cre recombinase from pancreatic-specific promoters to obtain Pdx-1-Cre/KrasG12D/ p53R172H (KPC) mice. Supplementary Table 2 In contrast, TAM-CM decreased caspase-3 activation in siControltreated cells, but had no effect on siCDA-treated cells.
Orthotopic tumor model
We used an orthotopic PDA murine model described elsewhere. 30 Panc2 or KPC mouse cells were harvested from confluent cultures, washed with PBS and resuspended. The mice were anesthetized with ketamine-xylazine 0.2 cc/20 g mouse weight. A left lateral abdominal incision was made, the peritoneum was opened, and the part of the pancreas near the portal area of the spleen was well exposed. A total of 10 6 cells in 50 ml of PBS were injected into the pancreas using an inoculator with a 30-gauge needle. Gemcitabine powder was purchased from Sigma (Rehovot, Israel) and resuspended in sterile H 2 O at 5 mg/ml. Gemcitabine treatment (80 mg/kg; q3 days) with or without GW2580 (LC Laboratories, Woburn, MA, USA) or vehicle (80 mg/kg, b.i.d.) was initiated 7 days after implantation by intraperitoneally. The mice in the control groups were injected i.p. with PBS twice weekly. The mice were killed 3 days after the last injection, and the pancreases were harvested. Long (L) and short (S) axes of each tumor were measured with calipers, and tumor volume (V) was calculated as follows:
2 ). The KPC cell line was established from freshly isolated tumor specimens that were minced with sterile razor blades, digested with dispase II/ collagenase (4 mg/ml each) for 1 h at 37 1C, and then resuspended in RPMI and 20% fetal calf serum and seeded onto ornithine-coated plates. Cells were passaged by trypsinization. All studies were done on cells cultivated for less than seven passages. PCR was done to assess the presence of the WT Kras and KrasG12D mutant transcripts using primers KRAS1, 5 0 -AGGCCTGCTGAAAATGACTG-3 0 and KRAS7, 5 0 -CCCTCCCCAGTTCTCATJ;GTA-3 0 , to amplify a 243-bp product from both the WT and mutant transcripts. Then, PCR products were subjected to direct sequencing with one of the primers used in the PCR.
Clodronate depletion was performed as described earlier. 32 Clodronate and PBS-containing liposome were purchased from http:// clodronateliposomes.org. Two weeks after orthotopic implantation of KPC4139 PDAC tumor cells into the pancreas, the mice were randomly assigned to receive the following treatments (n ¼ 5 for each group): (1) i.p. injection of clodronate-containing liposome (200 ml) 3 times/week or (2) i.p. injection of PBS-containing liposome with similar dosing (control group). Gemcitabine treatment was initiated in both groups 48 h later. All the mice were treated for 3 weeks.
Tumor imaging and analyses
During the imaging procedure, mice were anesthetized with 2% isoflurane vaporized in medical air. Animal temperature was monitored and maintained at 37 1C with a heated imaging platform. Tumor volume assessments were made by high-resolution sonography that was performed by a technician expert in small animal imaging blinded for treatment groups. Imaging was performed with a Vevo 2100 small animal micro-imaging system (VisualSonics, Toronto, ON, Canada) using a 40-Mhz ultrasound probe with axial resolution of 40 mm and a 14.6-mm field of view. The pancreatic tumor region of interest was selected by obtaining cine loops of ultrasound image and an image frame showing the tumor at its largest transverse diameter was selected for analysis. Two-dimensional images were initially acquired at regular spatial intervals, which were parallel and uniformly spaced at 100 mm. Long (L) and short (S) axes of each tumor were measured and tumor volume (V) was calculated as follows: V ¼ 0.52 (L Â W 2 ) Â 0.3. Mice were treated for 3 weeks and the sonographic volume measurements were performed before treatment at days 5, 10, 15 and 21.
Immunohistochemistry staining and analysis
Immunohistochemistry staining was performed with rabbit monoclonal anti-CDA Ab (IgG, 1:50; Abcam, Cambridge, UK), rabbit polyclonal anti-Ki67 Ab (IgG, 1:100; Abcam) and rabbit polyclonal anti-active caspase-3 Ab (IgG, 1:10; Abcam). Hydrogen peroxide-labeled tissues were visualized by using DAB as a substrate (Abcam). Individual tissue sections were deparaffinized, rehydrated and incubated with fresh 3% hydrogen peroxide in methanol for 15 min. After rinsing with PBS, samples were immersed in 0.01 M sodium citrate buffer (pH 6.0) and heated in a microwave oven at 100 1C for 15 min for antigen retrieval. Non-specific binding was blocked by incubating the sections with normal albumin for 30 min at room temperature. Quantification of immunostained cells was performed as follows: each slide was observed under the Â 40 objective or higher and digital pictures were taken and stored as image files (Olympus, San Diego, CA, USA). The high power field was equivalent to 0.34 mm 2 on the original slide. In each picture, positive cell was counted and the number of positive cells per high power field was calculated.
Statistical analysis
The non-parametric Mann-Whitney U-test and the Kruskal-Wallis test were used for analysis of variance. Pearson's correlation coefficient and the nonparametric, Spearman correlation coefficient were used to test the strength of the relationship between the number of TAMs per high power field (TAMs density) and tumor volume. All P-values were calculated by two-sided tests using the Origin statistical package (OriginLab Corporation, Northampton, MA, USA). Po0.05 was considered as statistically significant. Standard deviations are depicted by error bars in the graphs. All experiments were repeated at least three times. Data from representative experiments are shown.
